Literature DB >> 15026749

[Dapsone treatment of folliculitis decalvans].

P Paquet1, G-E Piérard.   

Abstract

BACKGROUND: Folliculitis decalvans consists of recurrent patchy painful folliculitis of the scalp causing scarring alopecia. The physiopathology of this condition is still unclear, but is likely a manifestation of chronic neutrophilic bacterial folliculitis. Numerous topical and systemic treatments (corticosteroids, antistaphylococcal antibiotics) have been used with variable results. Based on the dapsone antimicrobial activity and its anti-inflammatory action especially directed to the neutrophil metabolism, we treated two patients with severe folliculitis decalvans with this drug. CASE REPORTS: The patients were treated with dapsone at a daily dose of 75 and 100 mg, respectively for 4 to 6 months. After 1 and 2 months, pustular folliculitis progressively cleared, leaving a residual non inflammatory cicatricial alopecia. When maintaining a dapsone dosage at 25 mg/day no relapse occurred during 3 years and 1 year, respectively. No important adverse effect to dapsone was evidenced. After dapsone withdrawal, a moderate relapse of the disease with pruritus and folliculitis occurred after a few weeks in both cases. The disease relapse rapidly cleared after dapsone reintroduction at a daily dose of 25 mg. COMMENTS: Dapsone at moderate dosage was well tolerated and rapidly effective in treating the two cases of folliculitis decalvans. A long term and low dose (25 mg daily) maintenance treatment avoided disease relapses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15026749     DOI: 10.1016/s0151-9638(04)93570-3

Source DB:  PubMed          Journal:  Ann Dermatol Venereol        ISSN: 0151-9638            Impact factor:   0.777


  2 in total

Review 1.  [Topical therapy of the scalp].

Authors:  J Wohlrab; J Michael
Journal:  Hautarzt       Date:  2017-06       Impact factor: 0.751

2.  Folliculitis decalvans and orofacial granulomatosis.

Authors:  Kaja Męcińska-Jundziłł; Agnieszka Białecka; Urszula Adamska; Grażyna Kupś-Chmara; Aleksandra Grzanka; Rafał Czajkowski
Journal:  Postepy Dermatol Alergol       Date:  2018-06-18       Impact factor: 1.837

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.